Skip to content
TrialScanner

NCT06751524

Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval

No phase registeredAvailableAGENLead

Registry record

Lead sponsor
Agenus Inc.
Conditions
Colorectal Cancer (CRC); Pancreatic Cancer; Non-Small Cell Lung Cancer (NSCLC); Hepatocellular Carcinoma (HCC); Melanoma
Primary completion
Not registered
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT06751524 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.